Corcept Therapeutics (NASDAQ:CORT) Lowered to “Hold” Rating by StockNews.com
StockNews.com downgraded shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a buy rating to a hold rating in a research note released on Friday morning. Several other research firms have also recently weighed in on CORT. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave […]
StockNews.com downgraded shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a buy rating to a hold rating in a research note released on Friday morning. Several other research firms have also recently weighed in on CORT. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave […]
